A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies.

Purpose: We report our clinical experience with 32 patients receiving concurrent irradiation and capecitabine.
Methods and Materials: Medical records of patients with gastrointestinal malignancies treated with radiation and capecitabine therapy were reviewed.
Results: The population consisted of 20 males and 12 females, with a median age of 67.5 years (45-84 years) and adequate hepatic and bone marrow function. Histology was adenocarcinoma in all patients, except two with esophageal squamous carcinoma. Twenty-one patients received the regimen as adjuvant therapy, three received preoperative therapy, and 8 patients received therapy for palliation. The median dose of capecitabine was 1600 mg/m(2)/day (1200-2500 mg/m(2)/day) orally for 5 days per week for the duration of radiation therapy. Thirty patients received a total dose ranging from 45 Gy to 64 Gy over 4-6 weeks. Two previously radiated patients received total doses of 29.9 Gy and 46 Gy. Grade 3/4 toxicities observed were neutropenia in 3 patients and diarrhea, thrombocytopenia, fatigue, and myocardial infarction in 1 patient each. No treatment-related mortality was observed. Twenty of 21 patients (95.2%) who received adjuvant therapy continue to be in complete remission. Four of 11 (36%) evaluable patients demonstrated a response.
Conclusion: Concurrent capecitabine and radiation were very well tolerated and warrant further investigation in prospective trials.